MedTrace Logo

Effect of Vivomixx® on Neuroinflammation in Patients Withs Cirrhosis

NCT03236090 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2018-03-13

No results posted yet for this study

Summary

Study Design:

Double-blind randomized placebo-controlled clinical trial

Study Duration:

2 years

Study Center:

Single center Hospital de la Santa Creu i Sant Pau, Barcelona

Objectives:

To assess the effect of Vivomixx® on neuroinflammation and systemic inflammatory response in patients with cirrhosis

Conditions

  • Cirrhosis, Liver

Interventions

DIETARY_SUPPLEMENT

Vivomixx

Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)

Sponsors & Collaborators

  • Spanish Clinical Research Network - SCReN

    collaborator NETWORK

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-15
Primary Completion
2018-03-09
Completion
2018-03-09

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03236090 on ClinicalTrials.gov